Managing Difficult Experiences in Psychedelic-Assisted Therapy: What "Bad Trips" Actually Are and How They're Handled

The phrase "bad trip" is a cultural inheritance from the recreational era of psychedelics. It is not a clinical category, and it does most of its work by collapsing two very different things — acute distress that is part of therapeutic work and adverse outcomes that warrant clinical concern — into a single frightening label. In modern psychedelic-assisted therapy, clinicians use "challenging experience" or "difficult experience" instead, because the distinction between challenging and harmful is the distinction between something a clinical team is trained to hold and something that triggers a different protocol. This article is a Canadian guide to what difficult experiences actually look like in psychedelic-assisted therapy, why they are not always bad, how clinical teams respond to them, and what genuine safety concerns warrant a different response.

Key takeaways

• "Bad trip" is colloquial, not clinical. Clinicians use challenging experience or difficult experience because the distinction between challenging and harmful is the distinction that drives clinical response.
• Challenging experiences are common and often therapeutic. Acute fear, ego dissolution, trauma surfacing, intense emotion — when held in a supportive container, these are frequently where the work happens (Carbonaro 2016, PMID 27909164).
• Harmful experiences are different. Prolonged psychiatric distress, trauma worsening, persistent psychotic symptoms, suicidality, and HPPD are clinical events with distinct response protocols.
• Clinical teams have a graded response toolkit: non-directive presence, verbal grounding, body-based grounding (with consent), music adjustment, position change, de-escalation, and — rarely — pharmacological rescue.
• Preparation and integration substantially reduce destabilization. Difficult material in a well-prepared patient with a strong post-session integration plan tends to translate into therapeutic work; the same material in unsupervised or unprepared use does not.
• Self-led, festival, and unsupervised use carry a fundamentally different risk profile from a clinical context. This article describes the clinical context.
• Honest framing: psychedelic experiences are not always pleasant or easy, and the therapeutic value is often in working through difficulty rather than in avoiding it.

Why clinicians don't say "bad trip"

The term "bad trip" entered popular vocabulary through 1960s recreational use and 1970s prohibition-era media. It packs two assumptions clinicians need to separate:

1. That intensity, fear, or distress during a psychedelic experience is itself a bad outcome.
2. That every difficult moment is the same kind of clinical event.

Neither is correct. Acute distress within a contained, supported session is frequently the precursor to therapeutic insight. And the clinical handling of, say, ten minutes of acute fear is fundamentally different from the handling of an emerging psychotic episode or post-session suicidality. Collapsing them under "bad trip" makes both worse — it pathologizes ordinary therapeutic intensity and underweights genuine safety events.

The contemporary literature uses "challenging experience" (Carbonaro et al. 2016, J Psychopharmacol, PMID 27909164) and "difficult experience" interchangeably. This article uses both, and reserves "harmful" or "adverse event" for outcomes that meet a clinical threshold.

Challenging vs harmful: the distinction that matters

The most important framing in this whole topic.

Challenging experiences are acute, time-limited phenomena that arise during or shortly after dosing and that resolve as the medicine clears or with the team's support:

• Acute anxiety, fear, or panic
• Ego dissolution and "death anxiety" — the experience of self-boundaries softening or dropping
• Trauma material surfacing — old memories, body sensations, relational patterns
• Paranoia or transient suspicious thinking
• Nausea and physical discomfort
• Time distortion — minutes feeling like hours
• Confusion or disorientation
• Crying, intense emotional release, or grief surfacing
• Sense of losing control

These are uncomfortable. They are also, in a well-supported clinical context, frequently the texture of therapeutic work. Carbonaro et al.'s 2016 Hopkins survey of 1,993 individuals reporting challenging psilocybin experiences found that despite acute distress, 84% reported the experience as personally beneficial in retrospect, and 76% reported increased well-being or life satisfaction. Personal meaning attached to the experience predicted retrospective valuation; acute distress did not predict harm.

Harmful experiences are events that meet a clinical threshold for adverse outcome:

• Prolonged psychiatric distress lasting beyond the integration window
• Worsening of trauma symptoms (re-traumatization rather than processing)
• Persistent psychotic symptoms
• Acute or post-session suicidality with plan or means
• Cardiovascular instability requiring medical intervention
• HPPD (Hallucinogen Persisting Perception Disorder) — visual perceptual changes lasting weeks to months
• Long-lasting psychiatric difficulties

These warrant distinct clinical response. They are uncommon in a well-screened, well-prepared, well-set clinical context (McCorkindale 2024, adverse-events review). They are not unheard of. And the clinic's job is to anticipate, prevent where possible, and respond appropriately when they occur.

The line between challenging and harmful is not always clean in real time, which is why a trained clinical team — not a sitter, not a friend — is the right context for psychedelic-assisted therapy.

What challenging experiences actually look like

A non-exhaustive map, drawn from the controlled-trial and clinical-observation literature.

Acute anxiety and fear. Often early in the dosing arc, sometimes peaking with onset, sometimes with the loss of familiar perceptual cues. Patients describe feeling overwhelmed, frightened, or "wanting it to stop." This is one of the most common difficult moments and is highly responsive to grounding.

Ego dissolution and death anxiety. Particularly with higher psilocybin doses and to a lesser extent with high-dose ketamine and MDMA. The experience of self-boundaries softening, time and identity becoming unclear, or a sense that "I am dying" can be terrifying when first encountered. The clinical literature on psilocybin (Carhart-Harris 2016; Griffiths 2016) treats ego dissolution as a phenomenon that, when held in a supportive container, can be associated with positive therapeutic outcomes — and as a phenomenon that is acutely distressing in the moment.

Trauma surfacing. MDMA-AT and to a lesser extent ketamine and psilocybin can bring trauma memories, body sensations, and relational patterns into vivid awareness. The MAPS MDMA-AT manual (Mitchell 2021/2023, MAPP1/MAPP2) is built around the assumption that trauma material will surface and that the clinical task is to help the patient stay with it rather than dissociate from it.

Paranoia. Transient suspicious thinking — feeling watched, mistrustful of the team, interpreting neutral cues negatively — can arise particularly with psilocybin. It generally resolves as the medicine clears and is responsive to verbal orientation.

Physical discomfort. Nausea is common with psilocybin (often in the first 1–2 hours) and with MDMA. Bruxism (jaw clenching) is characteristic of MDMA. Muscle tension, temperature changes, and cardiovascular sensations all occur. These are usually manageable with positional changes, hydration, and time.

Time distortion. Minutes feeling like hours is one of the most consistent psychedelic phenomena. It can be unsettling — "this will never end" — and is responsive to verbal orientation.

Confusion and disorientation. Especially around onset and offset transitions. Patients may temporarily lose track of where they are, why, and who is present. The team's job is to orient gently and frequently.

Intense emotion and crying. Grief surfacing, joy surfacing, anger surfacing. Tears are not a sign that something is going wrong; they are often a sign the work is happening.

Why challenging experiences aren't necessarily bad

The default assumption — that distress is a sign of failure — is the wrong one for this context. Three threads of evidence push the opposite direction.

1. The Carbonaro 2016 survey on challenging psilocybin experiences. Carbonaro et al. surveyed 1,993 people who self-reported "the single most psychologically difficult or challenging experience" with psilocybin. Despite the acute difficulty — 39% described it as among the top five most challenging experiences of their lives — 84% reported the experience as personally beneficial in retrospect. Personal meaning, sense of insight, and the supportiveness of the context predicted retrospective valuation more strongly than acute intensity did.

2. The "the medicine shows you what needs healing" framing. This is not magical thinking; it has a mundane neurobiological reading. Psychedelics appear to soften the predictive priors that ordinarily filter what the mind attends to (Carhart-Harris and Friston 2019). What surfaces is often material the patient has been working not to attend to — defended-against memories, body states, relational patterns. That material is, almost by definition, uncomfortable. The clinical task is not to prevent it from surfacing but to help the patient stay with it long enough that something useful happens.

3. Resistance is often where the work lives. Across psychotherapy traditions — and explicitly built into MAPS-style MDMA-AT — the moments a patient most wants to flee are often the moments most worth staying in. The team's role is not to engineer comfort; it is to support the patient through difficulty.

This is the framing Hartogsohn (2017) calls "the trip is not the therapy." The substance produces a non-ordinary state. The therapeutic value is in what the patient and team do with the state — including the difficult parts of it.

How clinical teams respond to difficult moments

The MAPS, COMPASS, and Imperial College manuals — and clinical KAP literature — converge on a graded response toolkit. The principle is least-intervention-first: support the patient through the experience without prematurely terminating or pharmacologically interrupting it, unless a higher-acuity threshold is crossed.

Non-directive presence. The first and most common intervention is the team's continued, calm, non-anxious presence. The clinician does not steer content; they sit with it. This is the dominant posture across MAPS MDMA-AT, COMPASS COMP001 psilocybin, and KAP protocols.

Verbal grounding and orientation. Brief, low-volume, factual statements: "You're safe. You're at the clinic. We're here. The experience will pass. Whatever is coming up, you can stay with it." Orientation is offered, not imposed; the patient is not pulled out of the experience unnecessarily.

Body-based grounding — with explicit pre-session consent. Touch (commonly a hand on the forearm or shoulder) is part of the MAPS MDMA-AT manual specifically because trauma work benefits from co-regulated nervous-system contact. Touch is only used with written consent obtained in preparation, and the consent specifies what kind of touch, where, and that it can be withdrawn at any moment. A weighted blanket can provide proprioceptive grounding without interpersonal touch. Cold stimulation (a cool cloth, ice held briefly) can interrupt panic spirals. The choice between modalities is patient-led.

Music adjustment. Pace and emotional tone of the playlist are clinical variables (see the set-and-setting article). The team can shift to gentler or more containing music if the current track is amplifying difficulty in an unhelpful direction, while taking care not to override an emotional arc that is doing useful work.

Position change. Sitting up, lying down, moving to a different chair, going to the bathroom briefly. Small changes in physical position can shift intensity.

Verbal de-escalation. Slow paced breathing led by the clinician, naming what is happening ("This is the medicine; it will pass"), and brief somatic exercises learned in preparation.

Pharmacological rescue — rarely. In the rare event that acute distress is severe and unresponsive to the above, a benzodiazepine (commonly lorazepam) can be used to reduce psilocybin or MDMA acute effects. This is not first-line; it is a defined escalation with a clinical threshold. Pharmacological rescue is generally not appropriate for ketamine (ketamine is short-acting and benzodiazepines do not reverse it; benzodiazepine sedation with ketamine carries respiratory considerations). The team's preparation includes the threshold for rescue, the medication available, and the documentation expected after.

The toolkit is graded so that the most preserving intervention — non-directive presence — is tried first, and pharmacological intervention is reserved for situations where the clinical balance favours it. Most challenging moments resolve with the first three or four steps.

Specific safety considerations: when a different protocol applies

Three categories of in-session events warrant a distinct response from the graded toolkit above.

Acute psychotic symptoms. Disorganized thought that does not track with the medicine arc, paranoid ideation that does not respond to orientation, fixed delusional content, or the appearance of an emerging psychotic episode. Personal and family-history screening in preparation is designed to keep these events vanishingly rare; when they do occur, the response involves careful clinical assessment, possible use of pharmacological intervention, and post-session psychiatric follow-up rather than continuation of psychedelic-assisted therapy.

Suicidality during or after the session. Any expressed plan, intent, or means warrants standard suicide-safety protocols: assessment, safety planning, escalation to psychiatric care as clinically indicated, and arranged follow-up. See Psychedelic-Assisted Therapy and Suicidality: What the Evidence Says for the detailed framing.

Cardiovascular instability. Active vital-signs monitoring is part of every dosing session for a reason. Hypertensive response, tachyarrhythmia, or other cardiovascular events trigger medical intervention and, depending on severity, transfer of care. Pre-session cardiovascular screening is the strongest determinant of how often these events arise.

The clinical principle across all three is that the team's response is driven by the threshold the event meets, not by the team's emotional reaction to it.

Why preparation reduces destabilizing experiences

The clearest cross-protocol finding is that well-prepared patients have fewer destabilizing challenging experiences and report greater retrospective benefit when challenging experiences do occur. The mechanism is not mysterious:

• Patients who know what ego dissolution feels like in advance are less likely to interpret it as dying.
• Patients who have practiced grounding skills in preparation can use them in the room.
• Patients who trust the team will reach for support rather than spiral alone.
• Patients who have set intentions have a reference point to return to when content gets disorienting.
• Patients who have screened cleanly are less likely to encounter the rare adverse events.

This is the operational reason the preparation phase is a non-skippable part of psychedelic-assisted therapy. It is also why programs that compress or skip preparation are taking on risk that the better-evidenced protocols specifically engineer against.

Why integration matters — including for difficult experiences

A challenging experience that lands without support tends to consolidate as confusion, fear, or — at worst — long-tail distress. The same experience, processed in integration, tends to consolidate as insight or behavioural change. Integration after a difficult session is not optional; it is where the difficulty becomes useful or doesn't.

Integration after a difficult dosing session typically includes a same-day check-in (brief, focused on stabilization), a 24–72 hour structured integration session (focused on meaning-making and somatic processing), and follow-up integration over weeks. The team's framing throughout is that acute distress in a contained session is workable material, and the patient's job is not to make sense of it alone.

"The trip is not the therapy" — Hartogsohn's framing

Ido Hartogsohn (2017) put it crisply: the substance produces a non-ordinary state, but the therapeutic value emerges from what is done with the state. The corollary is that a session containing a difficult experience is not a failed therapy session, and a session containing a smooth experience is not automatically a successful one. The therapy is the preparation, the in-session relational work, and the integration. The substance is the catalyst the work happens around.

This framing matters because it allows clinicians and patients to relate to difficulty without panic. A challenging experience is the work showing up. The team's job — and the patient's, in collaboration — is to meet it.

Self-led, festival, and unsupervised use is a different thing

Most of what enters public consciousness as "bad trip" stories arises in unstructured, unsupervised, recreational contexts: festivals, self-experimentation, peer-supplied substances of unknown purity and dose. Those contexts are not what this article describes. They differ from a clinical setting on every variable that matters:

• No medical screening
• No pharmacological characterization (purity, dose, contaminants)
• No prepared therapeutic alliance
• No trained clinical team in the room
• Often unsafe physical environment
• No integration structure
• No emergency medical capability

In those contexts, the rate and severity of difficult and harmful events is meaningfully higher. The harm-reduction literature (DanceSafe, Multidisciplinary Association for Psychedelic Studies harm-reduction services, Zendo Project) addresses this domain specifically. ATMA CENA operates in the clinical domain. The two contexts share pharmacology and almost nothing else. Patients who have had difficult experiences in unsupervised settings sometimes reach a clinical context with the wrong frame for what supported psychedelic-assisted therapy looks like; preparation explicitly addresses this.

How ATMA CENA's clinical environment supports difficult moments

ATMA CENA's dosing environment is designed against the framework above.

• Trained co-therapy or sitter team. The dosing room staffing is calibrated to substance and patient — psilocybin and MDMA-AT under SAP follow the two-clinician model in line with COMP001 and MAPP1/MAPP2 protocols; KAP staffing follows substance, dose, and clinical judgment.
• Pre-session consent for grounding modalities. Whether touch is used, what kind, and where, is negotiated and documented in preparation and can be withdrawn at any moment. Patients who do not want touch are not touched. Weighted blankets and cold stimulation are alternatives.
• Active medical monitoring. Vitals are tracked continuously across dosing. Emergency medications are present and protocols are rehearsed.
• Defined escalation thresholds. The team knows in advance what triggers a benzodiazepine rescue, what triggers psychiatric escalation, and what triggers cardiovascular response — these are not improvised.
• Same-day and 24–72 hour integration. A challenging session is followed by structured integration designed to do the meaning-making work the patient should not be doing alone.
• Coordinated care alignment. Where a patient has an existing therapist, ATMA CENA's coordinated care model extends post-session support across the existing therapeutic relationship — particularly valuable when integration of difficult material is the work.

HPPD and long-lasting psychiatric difficulties

Two small categories of post-session events warrant explicit naming because the literature describes them.

HPPD (Hallucinogen Persisting Perception Disorder). Halpern and Pope (2003, Drug and Alcohol Dependence) reviewed the HPPD literature: persistent visual perceptual changes (visual snow, trailing, halos, after-images) reportable as a discrete syndrome after psychedelic exposure. HPPD is rare in the controlled-trial literature; the bulk of reported cases arises in self-led recreational use, often with concurrent cannabis or other substance use, and often with multiple prior psychedelic exposures. It is documented; its mechanism is incompletely understood; and most cases are mild and self-limited. Severe HPPD is uncommon but real. Clinical screening reduces but does not eliminate risk.

Long-lasting psychiatric difficulties. The McCorkindale et al. adverse-events review across modern psychedelic clinical trials documents a small number of prolonged psychiatric difficulties — extended anxiety, depressive worsening, persistent dissociation — across pooled trial populations. The base rate is low in well-screened, well-set clinical contexts. It is not zero. Honest informed consent acknowledges this.

These categories are not reasons to avoid clinical psychedelic-assisted therapy in a screened, prepared, supported context. They are reasons the screening, preparation, and support exist.

Honest framing: psychedelic experiences are not always pleasant

The most important thing this article can do is replace one frame with another. The frame to retire is "the medicine should be calm and pleasant; if it isn't, something has gone wrong." The frame to install is "the medicine produces a non-ordinary state in which difficult material may surface, and the team's role — and the patient's, in collaboration — is to meet it."

Difficult moments in a clinical session are not failures. They are often the work. The role of preparation is to make those moments workable; the role of the dosing-room team is to hold them; the role of integration is to make use of them.

Psychedelic-assisted therapy is not a comfort intervention. It is a clinical intervention in which discomfort is sometimes the substrate of change. Honest framing serves patients better than reassurance does.

Frequently asked questions

Is "bad trip" a real thing? The phenomenology is real — acute distress during a psychedelic experience occurs and is well-documented. The label "bad trip" is not clinical and conflates challenging experiences (often workable, sometimes therapeutic) with harmful events (a different clinical category requiring different response). Clinicians use "challenging experience" or "difficult experience" instead.

How likely am I to have a difficult moment in a clinical session? Some intensity is the rule, not the exception, particularly with high-dose psilocybin and MDMA. Whether intensity rises to the level of acute distress varies by substance, dose, patient, set, and setting. Carbonaro 2016 documents that even substantial difficulty is often retrospectively valued; the cluster that produces lasting harm is meaningfully smaller than the cluster that produces difficult-but-useful moments.

Will the team stop the session if I'm scared? Generally, no — fear is not a reason to terminate. The team supports the patient through fear with grounding, presence, and the patient's prepared anchor skills. Pharmacological rescue exists for severe, unresponsive distress and is a defined escalation, not a default response. The aim is to support the patient through the experience, not to interrupt the medicine prematurely.

What is benzodiazepine rescue? The use of a short-acting benzodiazepine (commonly lorazepam) to reduce acute psychedelic effects when distress is severe and unresponsive to other interventions. It is a defined clinical escalation with a documented threshold, used for psilocybin and MDMA when warranted. It is generally not appropriate for ketamine. It is rare; most challenging moments resolve with non-pharmacological support.

Can the team touch me during the session? Only with explicit, written, pre-session consent that specifies what kind of touch and where, and only when the patient does not withdraw consent in the moment. Touch is part of the MAPS MDMA-AT manual specifically because trauma work benefits from co-regulated contact, but it is patient-led. Weighted blankets and other non-touch modalities are alternatives. Patients who do not want touch are not touched.

What is HPPD? Hallucinogen Persisting Perception Disorder — persistent visual perceptual changes (visual snow, trailing, halos, after-images) reported after psychedelic use. Rare in controlled-trial populations; primarily reported in self-led recreational use, often with concurrent substance use. Most cases are mild and self-limited; severe HPPD is uncommon but documented.

What if I have a panic attack in the session? Panic is one of the most common challenging experiences and is highly responsive to grounding, orientation, breathing, and the skills practiced in preparation. The team is trained for it. Patients who arrive having practiced anchor skills are equipped to use them when the moment comes.

What if trauma surfaces and I feel re-traumatized? Trauma surfacing is anticipated, particularly in MDMA-AT. The clinical posture is to support the patient in staying with the material at a tolerable window of intensity, with explicit somatic and verbal grounding. If the team's clinical assessment is that re-traumatization rather than processing is occurring, the response shifts toward containment, grounding, and post-session psychiatric care. Distinguishing the two is part of clinical training.

What happens if I have a difficult experience? Will it ruin the therapy? A difficult experience is not a failure; in many cases, it is the work. Same-day check-in and structured 24–72 hour integration is designed to translate difficult material into therapeutic use. Whether a difficult session was useful is generally clearer in integration, not in the dosing room.

Are festival or self-led "bad trips" the same thing as a difficult clinical experience? No. Self-led, festival, or unsupervised use occurs without screening, dose characterization, prepared alliance, trained team, or integration. Clinical psychedelic-assisted therapy occurs with all of those. The shared pharmacology does not make the contexts equivalent in safety or in therapeutic value.

Could I become permanently worse from psychedelic-assisted therapy? Long-lasting psychiatric difficulties are rare in screened, prepared, supported clinical contexts but not zero. Honest informed consent in preparation covers this directly. The screening, preparation, and support structure exist precisely to keep this rare.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada's Special Access Program on a case-by-case basis. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and within Canadian off-label prescribing principles. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

Sources

1. Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12):1268-1278. PMID: 27909164.
2. Hartogsohn I. (2017). Set and Setting, Psychedelics and the Placebo Response: An Extra-Pharmacological Perspective on Psychopharmacology. Journal of Psychopharmacology, 31(8):1259-1267. PMID: 28443452.
3. Halpern JH, Pope HG. (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence, 69(2):109-119. PMID: 12609692.
4. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
5. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37640273.
6. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
7. Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7):619-627. PMID: 27210031.
8. Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12):1181-1197. PMID: 27909165.
9. McCorkindale AN, Bradberry MM, Gukasyan N, et al. (2024). Adverse events in psychedelic-assisted clinical trials: a systematic review. Journal of Psychopharmacology. <!-- F2 FLAG: citation listed as "[in press / forthcoming reference]" — volume, issue, page, DOI, and PMID not yet filled in. Confirm final publication details and update. -->
10. Carhart-Harris RL, Friston KJ. (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews, 71(3):316-344. PMID: 31221820.
11. Johnson MW, Richards WA, Griffiths RR. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6):603-620. PMID: 18593734.
12. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html

Related articles

• The Preparation Phase of Psychedelic-Assisted Therapy
• The Integration Phase of Psychedelic-Assisted Therapy
• Set and Setting in Psychedelic-Assisted Therapy
• What to Expect at Your First Psychedelic-Assisted Therapy Session
• Psilocybin Side Effects and Safety
• MDMA-Assisted Therapy Side Effects and Safety
• Ketamine Therapy Side Effects
• Psychedelic-Assisted Therapy and Suicidality: What the Evidence Says

Last updated: 2026-05-06